Chief Executive Officer
Marc Beer brings over 20 years of development and commercialization experience in biotechnology, pharmaceuticals and diagnostics. In April 2000, Mr Beer became the founding CEO of ViaCell (VIAC), a biotechnology company specializing in the collection, preservation, and development of umbilical cord blood stem cells, and over a period of seven years led the company from its inception to a rapidly growing and robust commercial organization. Under Mr Beer's leadership, the company grew to more than 300 employees, went public in 2005 and was ultimately acquired in 2007 by PerkinElmer (PKI).
Prior to founding ViaCell, Mr Beer held various positions within Genzyme (GENZ), most recently as Vice President of Global Marketing where he was responsible for the commercial launch of several products addressing orphan disease populations on a global scale. Prior to Genzyme, he held a variety of sales and marketing roles in the pharmaceutical and diagnostic divisions of Abbott Laboratories (ABT). He also was a former member of the Mass Life Science Board of the Commonwealth of Massachusetts. Mr Beer serves on the Biotechnology Industry Organization (BIO) Emerging Companies Section Governing Board as well as on the board of directors of Good Start Genetics, Inc. where he is Chairman; ERYtech Pharma; Strategic Consultant to OvaScience; and a member of the Graduate Studies and Research Advisory Council of Notre Dame University. Mr Beer holds a B.S. from Miami University (Ohio).